CoChat

PIII-57Pharmacokinetics and dopamine D2 And serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: Two open-label, single-dose studies

KARLSSON, P, DENCKER, E, NYBERG, S, MANNAERT, E, BOOM, S, TALLURI, K, ROSSENU, S, ERIKSSON, B, EERDEKENS, M, FARDE, L · 2006 · Clinical Pharmacology & Therapeutics
Cited by 37

The DOI matches its Crossref record.

Abstract

OBJECTIVES Assess pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone immediate-release 1mg (paliperidone IR; Study 1) and paliperidone extended-release tablets 6mg (paliperidone ER; Study 2). METHODS Blood samples were collected pre-dose and ≤24h (Study 1) and ≤48h (Study 2). Striatal D2 receptor binding was measured using PET and 11C-raclopride pre-dose and post-dose at 2.5h (Study 1) and at 22h and 46h (predicted Cmax; Study 2). Frontal cortex 5-HT2A receptor occupancy (Study 1) was assessed using[11C]M100,907 ≥1 week pre-dose and 4.5h post-dose (Cmax). The apparent dissociation constant (KDapp=plasma concentration at which 50% of target receptor is occupied) was estimated using an Emax model. RESULTS Formulation differences were reflected in tmax and Cmax. Paliperidone ER 6mg corresponds to median D2 occupancy of 64% at 22h post-dose. Using the KDapp, plasma concentrations corresponding to 70–80% D2 occupancy were estimated: 15–25ng/mL (Study 1); 10–17ng/mL (Study 2). Using pooled data from both studies the in vivo KDapp is estimated to be 4.9ng/mL. CONCLUSION Paliperidone occupies central D2 and 5HT2A receptors. D2 receptor occupancy with paliperidone ER suggests 6mg will be an effective dose in the treatment of schizophrenia. (See Table) Measure Paliperidone IR 1mg*. Study 1 (n=3) Paliperidone ER 6mg*. Study 2 (n=4) Median Cmax (ng/mL) (range) 6.02 (5.34–6.14) 11.3 (7.73–16.5) Median tmax (h) (range) 4.2 (4.1–8.1) 24.1 (23.1–29.0) Median % D2 receptor occupancy (range) 48 (35–51)[2.5h post-dose] 64 (56–79)[22h post-dose]; 53 (40–62)[46h post-dose] Calculated KDapp for D2-receptor occupancy (ng/mL) 6.4 4.4 Median % 5-HT2A-receptor occupancy (range) 65 (65–71)[4.5h post-dose] Not measured Corresponding plasma concentration range (mg/mL) 5.1–6.0[4.0h post-dose] Not measured a Initial studies have shown that paliperidone ER has a bioavailability of approximately 33% of that of paliperidone IR. Clinical Pharmacology & Therapeutics (2005) 79, P74–P74; doi: 10.1016/j.clpt.2005.12.265

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.clpt.2005.12.265

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 37

Metadata

Authors
KARLSSON, P., DENCKER, E., NYBERG, S., MANNAERT, E., BOOM, S., TALLURI, K., ROSSENU, S., ERIKSSON, B., EERDEKENS, M., & FARDE, L.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2006-02
Volume
79
Issue
2
Pages
P74-P74
ISSN
0009-9236 (ISSN-L)
OpenAlex
W2315045824
Cited by
37
References
0
FWCI
2.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PIII-57Pharmacokinetics and dopamine D2 And serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: Two open-label, single-dose studies. https://app.cochat.ai/papers/10.1016/j.clpt.2005.12.265
The paper
KARLSSON, P., DENCKER, E., NYBERG, S., MANNAERT, E., BOOM, S., TALLURI, K., ROSSENU, S., ERIKSSON, B., EERDEKENS, M., & FARDE, L. (2006). PIII-57Pharmacokinetics and dopamine D2 And serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: Two open-label, single-dose studies. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/j.clpt.2005.12.265

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.